Although the above results and analyses in [21] suggested that high GPC3 expression in tumor is associated with the codrituzumab's benefit and there is a similar association for high CD16 expression in NK cells, these analyses only independently examined the individual association between a single biomarker, either GPC3 expression or CD16 expression, and codrituzumab's treatment effect and the following key questions remained to be answered: Whether a single biomarker, GPC3 alone or CD16 alone, is sufficient for Codrituzumab's therapeutic success? Here, GPC3 is linked to neoplasm.